Plasma-glycated CD59 as an early biomarker for gestational diabetes mellitus: prospective cohort study protocol.
Plasma-glycated CD59 as an early biomarker for gestational diabetes mellitus: prospective cohort study protocol.
复制标题
血浆糖化CD59作为妊娠期糖尿病早期生物标志物：前瞻性队列研究方案。
DOI：
10.1136/bmjopen-2021-054773
复制
发表时间：
2022-04-20
期刊：
影响因子：
2.9
通讯作者：
Halperin, Jose
中科院分区：
文献类型：
--
作者：
Andrews, Chloe;Toth-Castillo, Michelle;Aktas, Huseyin;Fernandez, Miguel-Angel Luque;Wong, Steven Koon;Sen, Sarbattama;Halperin, Jose
妊娠期糖尿病（GDM）的显著母婴结局使其成为一个主要的公共卫生问题。患有GDM的母亲患妊娠并发症的风险更大，其后代患糖尿病和肥胖症的风险更高。目前，GDM是用葡萄糖负荷方法诊断的，这种方法在怀孕期间进行多次给药既耗时又不方便;因此，人们认识到需要一种更准确、更简单的GDM检测方法。既往研究表明，血浆糖化CD 59（pGCD 59）是一种新的GDM生物标志物。我们在此介绍了一项前瞻性队列研究的方案，该研究旨在（1）确定pGCD 59作为妊娠期糖尿病和妊娠期糖耐量受损的早期妊娠预测因子的准确性，（2）评估pGCD 59水平与不良孕产妇和新生儿结局之间的相关性。我们将在两个时间点从孕妇中获得丢弃的血浆样本：首次产前访视（通常<14孕周）和妊娠24-28周。将使用研究特定病历提取工具从EPIC临床数据库中获取相关的孕产妇和新生儿临床数据。GDM的患病率将使用标准护理葡萄糖负荷试验结果确定。我们将确定pGCD 59预测GDM和妊娠期糖耐量受损诊断的敏感性和特异性，以及pGCD 59水平与孕产妇和新生儿结局患病率之间的相关性。本研究已获得Mass General Brigham机构审查委员会的批准（方案2011 P002254）。这项研究的结果将在国际会议上提出，并在同行评审的期刊上传播。
The significant maternal and neonatal outcomes of gestational diabetes mellitus (GDM) make it a major public health concern. Mothers with GDM are at greater risk of pregnancy complications and their offspring are at higher risk of diabetes and obesity. Currently, GDM is diagnosed with glucose load methods which are time-consuming and inconvenient to administer more than once during pregnancy; for this reason, there is a recognised need for a more accurate and simpler test for GDM. Previous studies indicate that plasma-glycated CD59 (pGCD59) is a novel biomarker for GDM. We present here the protocol of a prospective cohort study designed to (1) determine the accuracy of pGCD59 as an early, first trimester predictor of GDM and gestational impaired glucose tolerance and (2) assess the associations between pGCD59 levels and adverse maternal and neonatal outcomes. We will obtain discarded plasma samples from pregnant women at two time points: first prenatal visit (usually <14 weeks gestation) and gestational weeks 24–28. A study-specific medical record abstraction tool will be used to obtain relevant maternal and neonatal clinical data from the EPIC clinical database. The prevalence of GDM will be determined using standard of care glucose load test results. We will determine the sensitivity and specificity of pGCD59 to predict the diagnosis of GDM and gestational impaired glucose tolerance, as well as the associations between levels of pGCD59 and the prevalence of maternal and neonatal outcomes. This study has been approved by the Mass General Brigham Institutional Review Board (protocol 2011P002254). The results of this study will be presented at international meetings and disseminated in peer-reviewed journals.
登录
查看更多内容
影响因子：
81.5
作者：
McIntyre, H. David;Catalano, Patrick;Damm, Peter
通讯作者：
Damm, Peter
影响因子：
3.1
作者：
Jelsma JG;van Poppel MN;Galjaard S;Desoye G;Corcoy R;Devlieger R;van Assche A;Timmerman D;Jans G;Harreiter J;Kautzky-Willer A;Damm P;Mathiesen ER;Jensen DM;Andersen L;Dunne F;Lapolla A;Di Cianni G;Bertolotto A;Wender-Oegowska E;Zawiejska A;Blumska K;Hill D;Rebollo P;Snoek FJ;Simmons D
通讯作者：
Simmons D
DOI：
10.1016/s0002-9378(87)80045-5
发表时间：
1987-09-01
影响因子：
9.8
作者：
LANGER, O;BRUSTMAN, L;MAZZE, R
通讯作者：
MAZZE, R
影响因子：
9.8
作者：
Jensen, DM;Damm, P;Beck-Nielsen, H
通讯作者：
Beck-Nielsen, H
影响因子：
16.2
作者：
CEFALU, WT;PRATHER, KL;PERNOLL, ML
通讯作者：
PERNOLL, ML